Madhu Menon, MD, PhD, FCAP, ARUP’s section chief of Hematopathology, works with a team of experts to deliver accurate and timely results.
PhD scientists, analysts, and medical directors within ARUP’s Hematopathology department meet often to ensure clinicians and patients receive a diagnosis that reflects an integrated approach.
The AAV5 DetectCDx™ Kit received its Conformitée Européene (CE) mark in January 2022, and testing is being performed by a Medicover facility in Germany.
ARUP and Medicover have partnered to provide a new companion diagnostic test to European Union patients. The test helps identify individuals eligible for a new gene therapy for severe hemophilia A.
AAV5 DetectCDx™ detects the presence of anti-AAV5 antibodies to aid in the selection of patients eligible for the treatment ROCTAVIAN™.
ARUP has gained a Conformité Européenne (CE) mark for AAV5 DetectCDx™ single-site use. The test will aid in determining the eligibility of non-U.S. patients for a new hemophilia A gene therapy.
From left, Greg Critchfield, Myriad Genetics and Sera Prognostics; Mark Poritz, Co-Diagnostics; Kyle Berg, Quansys Biosciences; Jared Bauer, Seek Labs; Tracy I. George, ARUP Laboratories; and Andrew Hemmert, bioMerieux. These panelists addressed challenges facing diagnostics companies during a discussion at the Utah Life Sciences Summit in Salt Lake City on November 9.
A panel discussion at the Utah Life Sciences Summit explored how the FDA’s proposed rule to further regulate laboratory-developed tests could slow advances in diagnostic medicine.
Founding members of the new Institute for Research and Innovation in Diagnostic and Precision MedicineTM collaborate. From left, Erica Clyde, MBA; Robert S. Ohgami, MD, PhD, FCAP; and Hunter Best, PhD, FACMG.
ARUP experts in molecular pathology will present at, participate in, and be available to attendees during the upcoming Association for Molecular Pathology (AMP) Meeting and Expo in Salt Lake City.
ARUP’s Section Chief of Transfusion Medicine and Medical Director of the Transfusion Service, Ryan Metcalf, MD, contributed to recently updated guidelines for red blood cell transfusion by the Association for the Advancement of Blood and Biotherapies (AABB).
The Association for the Advancement of Blood and Biotherapies recommends that providers use a restrictive transfusion strategy to reduce unnecessary transfusions and the risk of adverse events.
The newest edition highlights innovations that keep ARUP at the forefront of toxicology testing. Also featured: ARUP’s expanded capacity for cytogenetics testing.
Dave Shiembob, manager of ARUP Healthcare Advisory Services, guides clients with utilization best practices and real-time opportunities.
A platform clients use to reduce testing waste, lower cost per test, and improve patient safety has won the prestigious Choosing Wisely Champion Award from the American Society for Clinical Pathology.
Founding members of the new Institute for Research and Innovation in Diagnostic and Precision MedicineTM gather. In the back row, from left to right, are David P. Ng, MD; Hunter Best, PhD, FACMG; Tracy George, MD; Leo Lin, MD, PhD; and Brendan O’Fallon. In the front row, from left to right, are Salika M. Shakir, PhD, D(ABMM); Robert S. Ohgami, MD, PhD, FCAP; Benjamin Bradley, MD, PhD; and Erica Clyde. Not pictured: Tatiana Yuzyuk, PhD, ABMGG; Evan Raps, MD; Peng Li, MD, PhD; and Valarie McMurtry, MD, PhD.
New ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ will improve patient lives by advancing groundbreaking diagnostic and prognostic technologies.
Dipanwita Banerjee, MS, associate scientist in Research and Development (R&D) Immunology, and Swapna Gudipaty, PhD, scientific manager of R&D Immunology, present their findings related to validation of a novel testing technology.
A novel event organized by ARUP’s Patent Committee aimed to highlight creative solutions that may not lead to patents but still advance laboratory medicine and improve patient care.
ARUP’s new test is the first companion diagnostic immunoassay for a gene therapy product to receive FDA approval. FDA has issued simultaneous approval of ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), BioMarin’s gene therapy for severe hemophilia A.
ARUP Laboratories has received FDA approval for its companion diagnostic immunoassay, AAV5 DetectCDx™, which helps determine patient eligibility for a new gene therapy for severe hemophilia A.
ARUP President and Chief Scientific Officer Tracy I. George, MD, pioneered the central pathology review service that screens and confirms potential patient candidates for clinical trials and monitors their drug responses.
ARUP’s Clinical Trials and PharmaDx groups supported Blueprint Medicines’ clinical trials that led to FDA approval for AYVAKIT® (avapritinib), a new treatment for indolent systemic mastocytosis.